Last reviewed · How we verify

NCT07051369

Frequency of Portal Hypertension Among Patient With Cirrhotic Liver With Ultrasound

Active, enrolled Last updated 4 July 2025
What this trial tests

trial testing Portal Hypertension diagnostics in Cirrhosis, Liver in 150 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
17 March 2025
Primary endpoint
1 September 2025
28 February 2026

Quick facts

Lead sponsorSuperior University
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment150
Start date17 March 2025
Primary completion1 September 2025
Estimated completion28 February 2026
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Superior University

Who can join

Adults 20 to 60, any sex, with Cirrhosis, Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Portal hypertension is a common and serious complication of liver cirrhosis, often leading to life-threatening conditions such as variceal bleeding, ascites, and hepatic encephalopathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cirrhosis, Liver

Currently open trials in the same condition.

Other Superior University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07051369.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing